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In order to provide a background to current concerns relative to the possible resistance of heartworms to
macrocyclic lactones, this review summarizes various studies in which lack of efficacies (LOEs) have been observed
in dogs on macrocyclic lactone preventives relative to the United States of America. Some of these studies have
been published in the peer-reviewed literature, others have appeared in various reports to the Center for Veterinary
Medicine (CVM) of the Food and Drug Administration (FDA) of the USA as New Animal Drug Application (NADA)
summaries, and one appeared as a letter to US veterinarians. This review also discusses reports relating to the
potential problem of heartworm resistance in microfilariae and third-stage larvae, as well as molecular markers
associated with resistance to macrocyclic lactones within Dirofilaria immitis. As more work is being done in this area
of great concern relative to the protection of dogs from infection using this class of preventives, it seems timely to
summarize what is known about heartworms, their potential resistance to treatment, and the means of selecting for
resistance genes in populations of this helminth in the laboratory and in the field.
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Emerging knowledge has brought to the forefront the
real possibility that resistance to macrocyclic lactones in
the canine heartworm Dirofilaria immitis is being
observed and could become a threat in the not too dis-
tant future. This information appears to contradict what
has been observed (or more specifically, not observed)
in human medicine, where more than two decades of
use of these compounds against similar human parasites
have not, thus far, resulted in significant problems of
resistance. As study progresses on the apparent loss
of efficacy of macrocyclic lactones in canine heart-
worm prevention, an understanding of the back-
ground (e.g., details of the preventive products and
their use, issues of compliance, genetics, and other
considerations) is necessary to ascertain the presence
of true resistance in the heartworm population.Correspondence: ddb3@cornell.edu
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reproduction in any medium, provided the orHeartworm prevention in dogs with macrocyclic lactones
and the choice of target doses for preventive treatment
The goal of heartworm preventive therapy in dogs has
been to stop infection by Dirofilaria immitis by killing
the stage that is deposited by the mosquito and first
enters the dog, the third-stage larva (L3), as well as the
young and maturing fourth-stage larva (L4). The selec-
tion of product doses to achieve this goal has often been
focused on a minimum effective dose, determined by
dose-titration studies using experimentally infected dogs;
the dose-limiting target organism, however, has not al-
ways been heartworms.
Two types of studies have been established as the rou-
tine method for testing monthly heartworm preventives:
dose-titration studies to determine the minimum effect-
ive dose against the helminth in question, D. immitis,
and dose-confirmation studies to verify that this mini-
mum dose is effective against two different isolates of
the helminth. The testing of the compounds is similar in
all cases as per requirements of the Center for Veterin-
ary Medicine (CVM) of the United States Food and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sign is the same in almost all cases (with one exception
that will be discussed below). Efficacy is determined by
giving dogs 30 to 100 L3 of D. immitis, and then 30 days
later (since the drug is labeled to be given monthly and
most products provide very little in the way of residual
compound within the dog after just a few days), the dogs
in the treatment groups are given the test compound
whereas control dogs either remain untreated or are
placebo-treated. Approximately five months after infec-
tion, all dogs in both groups are euthanatized and
necropsied, and the number of worms present in each of
the dogs is counted. This is the basic design for both the
dose-titration and dose-confirmation trials. In the dose-
titration trials, now being called dose-determination
trials by the CVM/FDA, there are typically four groups
of dogs: one that is treated at the expected target dose,
one that is lower than the expected target dose, one that
is higher than the expected target dose, and an untreated
control group. In the dose-confirmation trials, there are
only two groups of dogs – dogs treated with the target
dose and untreated controls. Dose-confirmation trials
are usually done as replicate studies in two different la-
boratories, each using a different isolate of the parasite.
Due to the perfect efficacy originally afforded by iver-
mectin, the efficacy for approval of heartworm prevent-
ive drugs was set at 100%. Thus, a single worm in a
dose-confirmation trial would preclude a drug from re-
ceiving approval. The single exception to this basic ex-
perimental design for the testing of all the products on
the market in the United States is ProHeartW 6, a slow-
release injectable product designed to prevent infection
for six months. Thus, for the ProHeartW 6 studies, dogs
in the treatment group are administered the product,
and then six months later both the treated dogs and the
untreated control dogs are inoculated with 30 to 100 L3;
five months after infection, these dogs are euthanatized
and necropsied to determine worm burdens. The differ-
ence in design is because this drug is expected to be
present in the dogs for six months, and thus, at six
months it must still provide 100% protection against
newly acquired infections. To reiterate, with most pre-
ventive products the drug is cleared fairly rapidly, and
the dogs are dosed monthly to kill any larvae that have
been acquired during the last 30 days. In contrast, the
level of ProHeartW 6 remaining within the dogs six
months after treatment is intended to be sufficient to
provide 100% protection against incoming larvae. These
are the two basic formulas for all the trials presented
below.
For Heartgard 30W (As marketed: tablets formulated
to supply a minimum effective dose band of 6 mcg
ivermectin/kg and a maximum dose of 12 mcg/kg),
the target was heartworm prevention. In the originalNADA 138–412 [1], "Of the 83 dogs treated at
monthly intervals in natural infection trials, or treated
30 days after induced infection, with doses of iver-
mectin at 3.0 mcg/kg or greater, only 2 dogs devel-
oped infections [Author’s note: the 2 dogs that were
positive were dogs that had each received 3.0 mcg/kg
on day 30 after having been infected with approxi-
mately 50 L3]. Even when the treatment interval was
extended to 45 or 60 days following infection, only 2
of 88 dogs given ivermectin at 6.0 mcg/kg or more
developed infections." Dogs receiving 6 mcg/kg at 45
and 60 days were negative at necropsy. Thus, the
minimal effective dose of 6.0 mcg/kg monthly was
chosen.
In the case of InterceptorW (As marketed: formulated
in a tablet to provide a dose band of 0.5-1.0 mg milbe-
mycin oxime/kg) (NADA 140–915), 0.05 mg/kg was not
always 100% protective against experimental heartworm
infections when administered 30 days post inoculation
with L3 [2]. However, a single treatment with 0.1 mg/kg
or more at 30 days post infection appeared 100% effect-
ive [2]. The higher dose of 0.5 mg/kg was eventually
chosen for this product in order to achieve >90% effi-
cacy against hookworms.
In the case of Revolution™ (As marketed: formulated
as a topically applied product to deliver a dose band of
6–13 mg selamectin/kg) (NADA 141–152) [3], the dose
was driven by flea control where "6 mg/kg of selamectin
was selected as a minimum dose for effectiveness against
fleas on dogs 30 days following a single topical adminis-
tration." For heartworms, "Selamectin applied topically
as a single dose of 3 or 6 mg/kg was 100% effective in
preventing the maturation of heartworms in dogs fol-
lowing inoculation with infective D. immitis larvae 30 or
45 days prior to treatment, and 6 mg/kg was 100% ef-
fective in preventing maturation of heartworms follow-
ing inoculation of infective larvae 60 days prior to
treatment."
In the case of ProHeart™ Tablets (As marketed: tablets
formulated to provide a dose band of 3–6 mcg moxidec-
tin/kg) (NADA 141–051) [4], "Moxidectin was 100% ef-
fective in preventing the development of a one month-
old heartworm infection of 50 L3 larvae of D. immitis in
dogs when administered as a single oral treatment at 1.5,
3.0, and 6.0 mcg/kg." In this NADA there were no dose-
confirmation studies with dogs receiving the 3.0 mcg/kg
target dose a month after experimental infection with 30
to 100 heartworm larvae. However, there was a second
dose-determination trial where “Moxidectin was 100%
effective in preventing the development of a two month-
old heartworm infection of 50 L3 larvae of D. immitis in
dogs when administered as a single oral treatment at
0.5 mcg/kg.” The target dose chosen for ProHeart™
Tablets was 3 mcg/kg.
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as an injectable slow-release product providing an initial
dose of 0.17 mg moxidectin/kg; there is no dose band
due to the formula allowing precise dosing) (NADA
141–189) [5], dosage titrations were performed with ini-
tial doses of 0.06, 0.17, and 0.50 mg/kg. In one study no
heartworms were recovered from any dogs receiving any
of the moxidectin-containing products, while in the
other study one dog in the lowest dose group was
infected. Thus, the minimum dose of 0.17 mg/kg was
chosen. This dose was also found to have excellent effi-
cacy against hookworm infections.
For Advantage MultiW for dogs (As marketed: formu-
lated in a topical application to provide a combination
product with a dose band of 2.5-6 mg moxidectin/kg for
heartworms and 10–25 mg imidacloprid/kg for flea con-
trol) (NADA 141–251) [6], the dosage was chosen based
on intestinal nematodes - "Dosage Characterization for
the Prevention of Heartworm Disease: Refer to section
e., Dosage Characterization for the Treatment and Con-
trol of Intestinal Nematodes, which establishes a mini-
mum effective dose for moxidectin." There was not a
dose titration performed since the target parasite was
not heartworm. In three trials, however, this minimum
dose of 2.5 mg moxidectin/kg protected all 44 dogs that
were treated 33 to 34 days after inoculation and 12 dogs
treated 45 days after inoculation.Control of filariid infections in humans
In human medicine, the target dose for the control of
the human filariid nematodes Onchocerca volvulus,
Wuchereria bancrofti, and Brugia malayi has not been
chosen for the purpose of preventing infection by killing
L3 and L4. Rather, the goal has been to suppress the
levels of microfilariae in the blood and skin of infected
individuals so that, although the adult worms survive,
there is no transmission between people. Also, the sup-
pression of the skin-dwelling microfilariae of O. volvulus
prevents the damaging effects of the microfilariae on the
cornea - the cause of river blindness. The dose chosen
for microfilarial suppression has been 200 mg/kg admi-
nistered orally every 6–12 months [7]. This increased
dosage is necessary because microfilariae are typically
less susceptible to macrocyclic lactones than are imma-
ture (L3, L4) filariid larvae. Although the campaign
against human filariasis has now been active for more
than twenty years with millions of doses being given to
people in the developing world, resistance has not
emerged as a significant problem; however, there are
some very recent indications that the duration of micro-
filarial suppression may not be as long as it once was
after treatment [8]. As yet, these effects do not appear to
be hampering the progress of control in the field.Factors that may influence the development of resistance
in heartworms
Two factors in the prevention of heartworm infection
are both likely to play major roles in how the different
drugs might lead to resistance or how they might differ
in their ability to affect resistant worms. First, as dis-
cussed above, canine heartworm preventives were
designed to prevent infection by killing L3 and young
L4. They were not designed to suppress microfilariae as
in the control of human filarial infections. If drugs at
preventive doses are given to dogs with existing infec-
tions, microfilariae will not be suppressed and many will
survive in spite of the fact that they have encountered a
macrocyclic lactone; these drug-selected microfilariae
can then be transmitted between dogs by mosquitoes.
Thus, use of preventives in microfilaremic dogs is a less
than prudent course since it might select for resistance
through the exposure of microfilariae to sublethal con-
centrations of macrocyclic lactones. Secondly, some of
the heartworm preventives on the market had other tar-
gets, such as fleas and intestinal nematodes, that
required higher doses for killing than did heartworm,
resulting in an increased minimum dosage for the com-
bination product. Very typically in the case of resistance,
increased doses of drug will continue to be efficacious
against resistant strains until selection is so marked that
the treatments become toxic to the host before the
worms are killed. In either case, with a resistant pheno-
type, if dogs are infected by L3 that develop to patency
in spite of exposure to a preventive, the ever-hardier
microfilariae will be capable of transmission by mosqui-
toes to other dogs. The concern is whether or not resist-
ant phenotypes of heartworms have already appeared in
the field.
What is resistance?
Resistance is defined by there being "a greater frequency
of individuals within a population able to tolerate doses
of a compound than in a normal population of the same
species and is heritable. . .. . .” [9]. Resistance to macro-
cyclic lactones is a well known phenomenon amongst in-
testinal nematodes. It has appeared in Haemonchus
contortus populations [10]; in populations of Parascaris
equorum [11]; and recent concerns have arisen relative
to the small strongyles of horses [12]. In these cases, the
target for control has been the adult worms using for-
mulations with 90% to 98% efficacy. Resistance is
selected by the repeated treatment of all animals, placing
significant selection pressure on the populations within
the intestine of the host. The worms that survive treat-
ment exposure are the only worms producing eggs for a
period of time, and this provides them with a competi-
tive edge. In the case of Haemonchus contortus, resistant
isolates have been maintained in sheep, and the heritable
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eration [13].
Potential arguments against the development of resist-
ance within heartworm populations might be the long
generation time, i.e., the 7-month-long life cycle, large
numbers of untreated refugia (stray dogs and, in the
USA, coyotes), and the perfect efficacy of the preventive
products against the highly susceptible L3. However, the
long life cycle and refugia are unlikely to play a role if,
for the former, resistant worms do not make a significant
trade-off in return for fitness, and for the latter, because
full reversion (i.e., loss of resistance) - as sometimes
occurs in bacteria when the drug pressure is removed -
has not been observed in nematodes [14]. Also, the
killing of a highly susceptible L3 stage by low doses of
product may not be of actual significance in delaying
resistance if, in the field, another more numerous and
more resistant stage, such as the microfilaria, becomes
the target of misdirected off-label treatment. That resist-
ance persists through worm developmental stages is
indicated by the success of the larval migration assay for
detecting resistance of adult H. contortus to macrocyclic
lactones [15].
Since drug resistance in nematodes does not seem to
impair fitness, the detection of this trait in any nematode
population is of significant concern. Treatment failures
in the field may be due to resistance, but often the true
cause is hard to pinpoint due to potential problems with
recording, lack of compliance, underdosing, reinfection
(or preinfection in the case of heartworm preventives),
etc. For some compounds, it is possible that resistance is
not inevitable for a plethora of factors that may be gen-
etic or related to management. As resistance of nema-
todes to various compounds, including macrocyclic
lactones, has been reported in a number of important
nematode parasites, it would seem that macrocyclic lac-
tone resistance amongst filariid nematodes is a real
threat. The current debate is whether or not the recent
reports of lack of efficacies (LOEs) with heartworm preven-
tives are due to the appearance of resistant forms or a con-
fluence of confounding factors such as poor compliance.The Mississippi delta and lack of efficacies (loes)
In the area extending along the Mississippi River from
Tennessee through Louisiana, there are many practi-
tioners who contend that the heartworm preventives
they have been using are no longer protecting dogs from
infection. On the other hand, it has been reported that a
very high percentage of these product failures are occur-
ring in pets where compliance has not been as good as
initially perceived by the claimant [16]. This speaks to
the continuing problem of trying to identify resistance in
the field, where treatment failures may or may notaccurately reflect an underlying issue of resistance. How-
ever, other knowledge has come to light in the past
18 months that suggests that the veterinary community
should be concerned about the threat of heartworm
resistance.
Microfilarial studies related to resistance phenotypes
Microfilariae have been purified from the blood of dogs
in the Mississippi Delta that were purportedly infected
with heartworms while on preventive therapy. These
microfilariae were examined for their ability to survive
in different concentrations of several macrocyclic lac-
tones [17]. Some of the isolates showing reduced suscep-
tibility to macrocyclic lactones were grown to the L3
stage in mosquitoes and used to infect dogs. When the
microfilariae from these latter dogs were examined in
the same assay, they were found to similarly lack suscep-
tibility to macrocyclic lactones. Thus, this observed lack
of microfilarial susceptibility to macrocyclic lactones is a
form of genetically inherited resistance; however, this
trait may or may not be linked to the ability of later
stages (i.e., L3 and young L4) to grow to adulthood in
dogs on preventive therapy. With the isolation of these
strains, experiments can now be designed to test
whether these isolates can successfully infect dogs on
preventive therapy.
Persistent microfilaremia in a Katrina rescue dog taken to
Canada and treated for its heartworm infection
Anecdotal reports by practitioners have circulated about
the inability to clear dogs of their microfilariae after the
adults are removed with ImmiticideW (melarsomine
dihydrochloride). Recently, a detailed case description
was published concerning one such case [18]. This was a
dog from the southern United States that was rescued
following hurricane Katrina and relocated to Canada
where it was treated with ImmiticideW for its heartworm
infection on two separate occasions, 5 months apart
[18]. The dog remained microfilaremic after the first
treatment in spite of being placed on a macrocyclic lac-
tone preventive product. Eight months after the first
adulticidal treatment, the dog had become antigen nega-
tive, but it remained positive for microfilariae in spite of
having received a second round of ImmiticideW and
multiple treatments with macrocyclic lactones including
two doses of ivermectin at 200 mcg/kg. The dog was
then treated every other week with milbemycin oxime,
ultimately near the top of the preventive dose band at
1.1 mg/kg, and finally daily for 7 days at 2.0 mg/kg fol-
lowed again a month later by the daily administration of
2.0 mg/kg for 8 days. The dog remained antigen negative
and microfilariae positive until just recently when the
microfilariae finally disappeared, more than two years after
the second adulticidal treatment (Personal communication
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verification that microfilariae that are refractory to macro-
cyclic lactones exist [17]. However, microfilariae from this
infection were not grown to L3 and used to infect another
dog, so it is not known whether this resistance trait was
inheritable, and again, there is no proof that the phenotype
of microfilarial resistance translates into resistance of L3
when they are inoculated into dogs receiving macrocyclic
lactones.
Susceptibility of third-stage larvae from mosquitoes to
macrocyclic lactones
Infective-stage heartworm larvae have been examined
for resistance to macrocyclic lactones using an assay
where L3 grown in mosquitoes are allowed to migrate
through fine mesh in the presence of different macrocyc-
lic lactone concentrations (a method originally devel-
oped to measure the prevalence of resistant phenotypes
in horse and sheep strongylids). L3 grown from the ap-
parently resistant microfilarial isolates from the Missis-
sippi Delta were found to be as susceptible to
macrocyclic lactones as L3 grown from non-resistant
microfilariae [19]. However, as with microfilarial suscep-
tibility, it remains unclear whether the phenotype of
decreased L3 susceptibility to macrocyclic lactones is
related to the ability to infect a dog on heartworm pre-
ventive therapy.
Lab-based studies with heartworms in dogs relative to
preventive product failures
In 2004, Pfizer Animal Health sent a letter to all veterin-
ary practitioners in the United States that informed
them that "An additional experimental study evaluating
the performance of RevolutionW involved mixed breed
dogs challenged with a rigorous infection of 50 heart-
worm larvae and treated 30 days later with a single dose
of Revolution™. . . .. The results indicated some treated
dogs harbored 1 or 2 adult heartworms five months fol-
lowing this laboratory challenge, all untreated control
dogs exhibited substantial worm burdens (14–43 adult
worms per dog)." This was the first report of laboratory
studies in which heartworms developed in dogs given a
single dose of a marketed preventive at the prescribed
dosage 30 days after inoculation with infective larvae of
a laboratory strain.
The development of TrifexisW
In 2011, two papers and the Freedom of Information
summary for the New Animal Drug Application
(NADA) appeared on the development of a new milbe-
mycin oxime-containing heartworm (HW) preventive
product, TrifexisW (As marketed: tablets formulated to
provide a dose band of 0.5-1.0 mg milbemycin oxime/kg
ion for heartworm with 30–60 mg spinosad/kg for fleacontrol) [20-22]. "To achieve a FDA-CVM-approved
label claim for HW prevention as determined in dose
confirmation (DC) testing protocols for these pioneer
ML [macrocyclic lactones], dogs were generally inocu-
lated with 50 infective D. immitis third stage larvae (L3)
obtained from experimentally infected mosquitoes, and
then 30 days later administered a single dose of the pre-
ventive being tested. A corresponding nontreated control
group was used to confirm adequacy of infection of the
HW isolate. Five to 6 months later, after surviving
worms have had a chance to mature, necropsy examina-
tions determine the effectiveness of the product. The
presence of a single HW in any of the treated dogs
would have prevented approval because 100% prevention
was necessary to obtain a label claim based on this dos-
ing protocol. . . ... As part of the development program
of an ML for HW prevention, 2 separate recently iso-
lated HW isolates were tested according to current
FDA-CVM requirements. While one isolate was fully
susceptible to this ML [macrocyclic lactone]providing
100% prevention after a single dose administered 30 days
after inoculation with HW L3, efficacy of a single treat-
ment against the second isolate was <100% [20]." In this
study, 3 of the 10 infected dogs treated with TrifexisW
had 3 worms at necropsy, 1 had 1 worm and 2 had 2
worms. This work was done with a strain identified as
MP3 - a heartworm isolate named after the naturally
infected dog from Georgia, USA from which it was iso-
lated, “Miss Piggy.”
The manufacturer of TrifexisW pressed forward with
its development and reported "A study was undertaken
with this second field isolate to assess the effectiveness
of currently marketed ML, in this case administering a
single dose of IVM [ivermectin] or MBO [milbemycin
oxime], in dogs challenged with HW L3 1 month before
treatment [21]." The products examined for preventive
efficacy were Heartgard Plus Chewables for DogsW (As
marketed: dose band of 6–12 mcg ivermectin/kg), and
Interceptor Flavor Tabs for Dogs & CatsW (As marketed:
dose band of 0.5-1.0 mg milbemycin oxime/kg). This
work was done in dogs with the MP3 strain using a
similar challenge model as already described [20]. There
was one worm found in one dog in each of the Heart-
gard PlusW- and InterceptorW-treated groups of dogs
(comprising 14 dogs each). Thus, neither product was
100% efficacious in preventing infection by the MP3
strain in this historical method of preventive testing.
In the development of TrifexisW, additional studies
were conducted with this strain examining the effects of
multiple treatments at 30 and 60 days after infection and
at 30, 60, and 90 days after infection. In the 10 dogs
treated twice with TrifexisW, there was a single worm
present at necropsy at 150 days postinfection (1 worm in
1 dog), whereas no worms were observed in the dogs
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statement "For heartworm prevention, give once
monthly for at least 3 months after exposure to mosqui-
toes “[22]. Continuing treatment for three months fol-
lowing the end of the mosquito season should protect
dogs from infection by killing any worms acquired dur-
ing the last month of transmission.
MP3 and Advantage MultiW versus Heartgard PlusW,
Interceptor Flavor TabsW, and Revolution™
In the introduction to a study that compared the efficacy
of these four products in dogs with a single treatment
30 days after inoculation with 100 L3 of the MP3 heart-
worm isolate, it is disclosed that the sponsor of the re-
search, Bayer Animal Health, LLC, as part of product
development, was working on a new macrocyclic
lactone-containing preventive (two formulations of
ivermectin-containing products with target minimum
doses of 6 mcg/kg and 9 mcg/kg; personal communica-
tion as to dose bands used) [23]. In this work using the
same dose of ivermectin as an already marketed product
or one that was at a dose 1.5 times higher, "a strain of
D. immitis (MP3 laboratory strain; TRS Laboratories
Inc., Athens, GA) was used to evaluate a potential new
anthelmintic product." It was found "In that study, the
MP3 laboratory strain was less susceptible to tradition-
ally effective doses of an ivermectin-based preventive in
a limited number of dogs." Thus, Bayer decided to
examine the efficacy of four commercial monthly pro-
ducts against this problematic strain.
The study design in this subsequent trial used 100 L3,
treatment with the labeled monthly dose 30 days later,
and necropsies 150 days after treatment. There were 8
dogs in each group. The results were such that 7 dogs
developed infections with adult worms in each of the
groups treated with Heartgard PlusW (0–7 worms), Inter-
ceptorW (0 to 6 worms), and Revolution™ (0–9 worms),
whereas no worms were recovered from any 8 of the
Advantage MultiW-treated dogs. Thus, again, with the
MP3 isolate, not all dogs were afforded 100% protection
by all products. In these single treatment studies, only
Advantage MultiW was 100% efficacious in preventing
development of the MP3 larvae to adulthood.
Summary of the above studies utilizing MP3
Among the studies discussed above, where the MP3
strain was used, there have been eight reported instances
in which dogs have become infected in spite of being
given a single heartworm preventive treatment 30 days
after infection: 1 study with TrifexisW, 2 studies with
Heartgard PlusW, 2 studies with InterceptorW, 1 study
with Revolution™, and 2 studies with ivermectin in a
product undergoing development. There was also one
study where one dog had one adult heartworm atnecropsy after having received two TrifexisW treatments
30 and 60 days after infection. Although F1 generations
of MP3 have been established (personal communications
to the author), there have been no reports as of yet on
whether the resistance trait seen with MP3 is heritable.
One might surmise, however, that worms that survive a
single treatment are perhaps more likely to produce off-
spring with a greater chance of surviving repeated
macrocyclic lactone preventive therapy than those killed
by a single treatment. Of course, it depends on whether
the trait is present in the genome of the worm and how
it is inherited by offspring when the worms mate.Additional studies with lack of efficacy
There has recently been another report of dogs not
being protected with milbemycin oxime at the same dos-
age as provided in InterceptorW, SentinelW, and Tri-
fexisW. In this case, SentinelW SpectrumW Tasty
Chews (a combination product of 0.5-1.0 mg milbemycin
oxime/kg, lufenuron, and praziquantel) was being brought
to market in the USA (NADA 141–333) [24]. The report in
the NADA approved in December of 2011 includes a trial
wherein the dogs were treated monthly for 6 months begin-
ning 30 days after infection with 50 D. immitis L3. In this
study, all treated dogs were protected. However, the NADA
states: "A 6-consecutive monthly dosing regime was
selected for effectiveness studies against D. immitis infec-
tions. Neither one dose nor two consecutive doses of SEN-
TINEL SPECTRUM provided 100% effectiveness against
induced heartworm (D. immitis) infections in dogs". The
label for this product states: "For heartworm prevention,
give once monthly beginning within 1 month of the dog’s
first seasonal exposure to mosquitoes and continuing until
at least 6 months after the dog’s last seasonal exposure." At
this point, it is unclear if this study was done using the
MP3 strain, but the work was performed in the laboratory
where the strain was first isolated and maintained, so it is a
possibility. If the strain was MP3, it would mean that there
is an additional study where milbemycin oxime was not ef-
fective in preventing the development of heartworms after
one or two treatments.Molecular biological examination of heartworms as
related to resistance
Recently the molecular phenotypes of heartworms have
been examined in an effort to see if various molecular
markers may be associated with treatment failures
[25,26]. The amount of polymorphism has been exam-
ined in different genes associated with macrocyclic lac-
tone resistance in other nematodes, e.g., the ABC
transporter gene - best known to veterinarians as the
PGP (P-glycoprotein-like) gene or the MDR1 (Multi-
Drug Resistance 1) gene - that is defective in dogs of the
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shown that in heartworms collected from around the
world, there were small differences in several of these
genes that appeared to be randomly distributed through-
out the population, i.e., the worms were polymorphic
within the gene examined. [Author’s note: A gene exhi-
bits no polymorphism if any change in the gene is fatal
to the worm, and if there is no polymorphism in a gene,
then it is of no value in determining whether or not drug
selection has an effect on the frequency of polymorph-
ism. Selection will produce reduced polymorphism in a
gene within a population; this is the classic selection for
pea color that led Mendel to his understanding of gen-
etic heritability.] In the case of D. immitis, these authors
found that the microfilariae produced by isolates from
the Mississippi Delta were markedly reduced in their
polymorphism for the genes examined. The authors con-
cluded that this indicated that selection, likely via
macrocyclic lactones, had driven worms toward genetic
similarity in those genes. Any selection in nematodes is
believed to be housed solely in the genome, so any
reduced polymorphism would also appear in all life
stages. These same investigators found a reduced poly-
morphism in the microfilariae from the Katrina rescue
dog in Canada whose microfilariae did not clear in the
presence of high doses of milbemycin oxime [18]. How-
ever, they have also examined these genes in MP3 and
have found that, based on the polymorphisms examined,
the genes from the MP3 strain appear susceptible but
with some degree of ML selection in its history but that
they have not undergone a high degree of loss of poly-
morphism when compared to that of the Mississippi
Delta isolates and the Katrina rescue dog [27].
So – do we have resistance?
Resistance can come about in several ways. It can be due
to a spontaneous mutation. It can be induced by muta-
gens, e.g., irradiation or chemical exposure. It can be
due to continued selection pressure - such as by
repeated treatment of worms with the same drug –
causing a particular phenotype to rise in frequency
within a population. In the case of heartworms, we can
probably rule out a mutagen-induced introduction of re-
sistance genes; thus, it is most likely that the resistance
is due to either a spontaneous mutation or via selection
of a rare or uncommon phenotype.
Mp3 as a spontaneous mutation
If with MP3 the resistance is heritable, i.e., microfilariae
produced by dogs infected with L3 derived from Miss
Piggy’s microfilariae are capable of infecting dogs receiv-
ing macrocyclic lactone preventives, then this is a strain
that is resistant to macrocyclic lactones. (It can be
argued that it is not fully resistant because multiplepreventive doses are protective, but it can also be readily
argued that it is a phenotype that undoubtedly has a
reduced susceptibility to macrocyclic lactones compared
to other strains that have been historically examined.) It
does not matter whether Miss Piggy’s population of
adult worms and their microfilariae ever saw macrocyc-
lic lactones before or not. If these microfilariae – which
have been shown to be less susceptible to heartworm
preventives – grow to adulthood and produce offspring
that can routinely infect dogs on preventives just like
their parents, they are resistant worms. This could be
due to a one-time chance event occurring from the
pairing of one male and one female worm within Miss
Piggy producing microfilariae with a resistant phenotype.
It may be that MP3 was simply a rare capture of a spon-
taneous mutation.
MP3 chosen by Selective Drug Pressure
It is also possible that the genes for resistance have
been in the genetic make-up of a small population
of D. immitis somewhere in the field for a very long time,
and via the widespread use of macrocyclic lactones, worms
in dogs were selected that have a resistant phenotype.
These already resistant worms then found their way via a
mosquito into Miss Piggy. Since both the ancestors of filar-
ial nematodes and the Actinobacteria producing the macro-
cyclic lactones occur within soil ecosystems, genes
supporting resistance to these bacterial products have likely
provided a survival advantage to nematodes for eons. The
genes only became important relative to drug resistance in
nematodes like Parascaris equorum and H. contortus when
we started using purified products from these Actinobac-
teria to treat or prevent nematode infections. Then, these
resistant phenotypes were promoted by selection. In this
scenario, the genes for resistance were already present in
the population and just never had a chance to show their
survival potential until challenged, such as occurred when
the MP3 isolate was captured and tested in the studies
described above.
When parasitologists think and talk about resistance
to anthelmintics they are usually considering the drug-
induced selection of resistant forms. The selection of
MP3 and possibly other heartworm strains in the United
States with resistance to macrocyclic lactones could
occur in at least two different ways. In one case, where
selection pressure may have been applied through regu-
lar preventive therapy, worms like MP3 - representing a
very small portion of the population - might sneak
through and survive in a few dogs on preventive. These
infections might remain undetected if dogs with devel-
oped adults and microfilariae did not receive annual sta-
tus checks, and the patent infections could then be
spread by mosquito transmission. In another case, the
adulticidal treatment of dogs with macrocyclic lactones
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by subjecting the off-target microfilariae to prolonged
drug exposure, select for populations of resistant circu-
lating microfilariae that are spread to new dogs by mos-
quitoes. In the first case, selection is at the level of L3
and L4; in the second case, selection would be occurring
at the level of the microfilariae.
Conclusions
At this point, it is not known if the F1 generation of
worms produced from microfilariae of LOE dogs in the
Mississippi Delta can develop to adults in dogs on pre-
ventive therapy. We do not even know at this time if
they can survive following a single preventive treatment,
as has MP3 in clinical drug trials. Based on the data to
date, it appears that the microfilarial assay used to evalu-
ate these isolates may measure a lack of susceptibility in
microfilariae, but this may not correlate with increased
survival of L3 (grown from those same microfilariae) in
the presence of these anthelmintics. Also, the isolates
from the Mississippi Delta and the Katrina dog that have
reduced sensitivity to macrocyclic lactones were different
than MP3 in that MP3 microfilariae appeared to be
more similar to the microfilariae of fully susceptible
forms based on certain gene polymorphisms. It is pos-
sible that the phenotype being examined in the microfi-
larial susceptibility assay might not be the same as that
required for resistance in larval and adult heartworms.
If the offspring of MP3 are found to behave the same
way as the original isolate in similar drug efficacy trials,
the trait is heritable, and resistance could be assumed. It
does not matter if the trait was due to spontaneous mu-
tation or selection. Again, because heritability of this
trait has yet to be shown for MP3, it cannot be stated
whether the resistant phenotype will persist into the next
generation. A spontaneous inheritable mutation event
would seem likely to occur with less frequency than
cases selected for by large-scale drug use in a population
where some worms already carry resistance genes. If the
problem with selamectin as reported by Pfizer’s 2004 let-
ter was due to a difference in the isolate used in those
trials, rather than due to some defect in product absorp-
tion or other product-associated problem, then this
could be considered evidence of either spontaneous
mutations occurring on more than one occasion or the
existence of a survival-promoting genetic trait in a num-
ber of heartworms within the general heartworm popu-
lation. Again, from the original HeartgardW 30 NADA
138–412, there were two dogs that developed heartworm
infections out of 83 dogs treated at 3.3. mcg/kg adminis-
tered 30 days after infection, and 2 dogs given 12 mcg/kg
ivermectin developed adult heartworm infections with
1 and 5 worms each, when product was administered
at 45 days and 60 days after infection (dogs getting 6mcg/kg at 45 and 60 days were negative at necropsy).
These results from sometime before 1987 suggest that
there is polymorphism in the worms relative to a po-
tentially resistant phenotype. This would lead to the
conclusion that there are resistance-associated pheno-
types occurring at some low level in the D. immitis
population.
Recently, there has been another study of the genetics
of heartworms in the United States. Using 11 poly-
morphic microsatellite loci and 192 individual heart-
worms from 9 different geographic locations in the
United States and Mexico, the genetics and population
structure of heartworms were examined and 4 major
genetic clusters were identified [28]. The clusters were
associated with the eastern United States, central USA,
western USA, and Mexico. There was a low level of het-
erozygosity observed in general, and high levels of recip-
rocal gene flow between the populations in the eastern
US and the central US. It appears that geographic bar-
riers impede significant gene flow between these areas
and California and Mexico. Germane to the conclusion
of this review is a conclusion reached by these authors
on the relationship between gene flow and resistance:
“This pattern of gene flow could certainly influence the
spread of alleles beneficial to canine heartworm. In an
area where there is a significant amount of gene flow,
such as the Gulf Coast, the dispersal of drug resistance
alleles would occur rapidly. Those resistance alleles
would not necessarily need to arise in that geographic
region, but could arrive there via dispersal from some
other area.”
At this point, careful study has begun into the issue of
resistance in heartworms, and the potential of resistance
existing has been taken seriously in many different la-
boratories. The life cycle of heartworms is long, and it
takes at least 6 months to develop adult worms and pro-
duce circulating microfilariae in a dog, and then another
6 months to determine if these microfilariae, when
grown to L3 in mosquitoes and used to infect additional
dogs, produce resistant worms. It also must be remem-
bered that worms, unlike bacteria, have to undergo gen-
etic recombination through mating between males and
females to produce offspring. What if there is only one
adult male in the MP3 population containing the resist-
ance trait? There is a good chance that a similar male
may not develop in the group of 30–50 worms in the
next infected dog. At this time, we do not even know
that the worms from an MP3 infection are capable of
producing microfilariae if the infections develop and
persist in the face of preventive therapy; the assumption
is that they would, but they might not. Overall, a pru-
dent approach remains similar to what has been recom-
mended in the past: Vigilance through testing dogs
before initiating heartworm prevention; vigilance
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letting any MP3 (or other potentially resistant strain) slip
by, live, and produce microfilariae while the dog is on
prevention; and vigilance through treating dogs with
adult worms with ImmiticideW rather than a macrocyclic
lactone, to reduce the chance of producing or selecting
microfilariae with a resistant phenotype. Furthermore, it
would be prudent to keep all dogs on year-round pre-
vention since this should reduce selection of worms that
have seen only one dose of drug due to a miscalculation
of the end of the transmission season, or because it
would appear that some strains, such as MP3, may re-
quire three consecutive doses of preventive to be fully
eliminated. It is critical that dogs on preventive be tested
annually and, if found infected, that the infection be
cleared using ImmiticideW. There is some indication that
doxycycline administration to dogs with adult worm
infections might suppress the infectivity to the next ca-
nine host of L3 that develop from microfilariae produced
by these doxycycline-treated worms [29], but the sample
size from this work is still very small, so it may not be
wise to count on this quite yet. Overall, at this time,
there is reason for concern, a lot of research that still
needs to be performed, a critical need for veterinarians
to impress upon their clients that they need to pay
attention to keeping current on their prevention, and
a need for veterinary practitioners to practice careful
record keeping while continuing to report all LOEs to
the FDA.
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